Skip to main content

Technology Transfer

Technologies protected in 2023

40

Applications filed
ICREA

EXPERIMENTAL SCIENCES & MATHEMATICS

Núria Aliaga
(ICMAB-CSIC)
  • Dispositivo de sublimación por vacío
Xavier Barril
(UB)
  • TREX Inhibitors
Jens Biegert
(ICFO)
  • Method for encoding information by valley polarization in a material
Gustau Catalán
(ICN2)
  • A flexoelectric material comprising water ice and water-soluble compound
José Ramón Galán-Mascarós
(ICIQ)
  • Method of synthesis of transition metal nitrides and their use when they have two, three or four metals as catalysts for the oxygen evolution reaction
Antón Vidal i Ferran
(UB)
  • Supramolecular hydroformylation catalyst
  • Supramolecularly enhanced regioselectivities towards lineal aldehydes in rhodium catalyzed hydroformylation (IMPRESH)
ENGINEERING SCIENCES
Xavier Costa Pérez
(I2CAT)
  • Computer implemented method, system and computer programs for locating a user equipment using an unmanned aerial vehicle
  • A computer implemented method, a system and computer program for estimating a target’s position
Gerasimos Konstantatos
(ICFO)

  • Confidencial titol
Arben Merkoçi
(ICN2)
  • A sintering method for obtaining nanostructured conductive nanoparticle films, nanostructured conductive nanoparticle film obtainable thereby and their uses
Josep Nogués Sanmiquel
(ICN2)
  • A method for magnetic conversion from paramagnetic to ferromagnetic of microporous metal materials, ferromagnetic microporous metal materia obtainable thereby and their uses
Valerio Pruneri
(ICFO)
  • Antimicrobial articles with a surface containing copper nanostructures, and methods of making
  • Apparatus for Optical Imaging
  • A versatile two-photon entanglement generation
Samuel Sánchez Ordóñez
(IBEC)
  • Catalase-powered nanobots for crossing mucus barriers
Jordi Sort Viñas
(UAB)
  • NI-Based porous electrode for water electrolysis and the preparation method thereof
Albert Tarancón
(IREC)
  • A process for manufacturing a functional electrochemical device based on a freestanding membrane
LIFE & MEDICAL SCIENCES
Joaquín Arribas
(PSMAR & VHIO)
  • Rodent models obtained by knock-in of the human HER2 gene
Christian Brander
(IRSICaixa)
  • CD33 as a biomarker of HIV control
Josep Dalmau
(IDIBAPS)
  • IFN – Signature as a biomarker for herpes simplex encephalitis related symptoms
  • New methods for the detection of neuronal antibodies
Xavier Daura Ribera
(UAB)
  • Klotho fusion protein and uses thereof
Roger Gomis
(IRB Barcelona)
  • New anti-cancer approaches
Pau Gorostiza Langa
(IBEC)
  • N-bridged diazocine analogues of carbamazepine to control neuronal activity with ligt and applications thereof
  • Compounds for sight restoration
Iñaki Martín-Subero
(IDIBAPS)
  • Prediction of tumour growth and prognosis
Javier Martínez-Picado
(IRSICaixa)
  • Antibodies and uses thereof for the treatment of infections caused by enveloped viruses
Pablo Menéndez
(IJC)
  • CCR9 Targeting moiety for the treatmenent of CCR9-positive cancer
Aurora Pujol Onofre
(IDIBELL)
  • Biomarkers discriminating the phenotypes of X-adrenoleukodystrophy
Ángel Raya Chamorro
(IDIBELL)
  • New methods for the detection of neuronal antibodies
Luis Serrano
(CRG)
  • Dual CSF-1 IL-10 cytokine
  • MadraX: Computer-implemented means and methods for the prediction of the stability of proteins and protein complexes
Manuel Serrano
(IRB Barcelona)
  • Small proteins for use as senolytic and senomorphic agents
Laura Soucek
(VHIO)
  • Method for assessing or monitoring the response to a cancer treatment
  • Combination therapy with MEK inhibitors for the treatment of cancer
  • Combination therapy with KRAS inhibitors for the treatment of cancer
  • Combination therapy with BRAF inhibitors for the treatment of cancer

Spin-off companies

1

Spin-off company created in 2023

Nanobots Therapeutics

Supported by the Institut de Bioenginyeria de Catalunya (IBEC) and ICREA
Entrepreneur: ICREA Research Professor Samuel Sánchez Ordóñez
Born in January 2023

Nanobots Therapeutics is a biomedical company developing a new modality of medicines for different types of cancers, based on our unique platform technology (MotionTx).

Our mission is to develop more effective therapies for patients by increasing drug penetration into cancer cells.

We’re utilizing our proprietary MotionTx technology platform to design, engineer, and develop therapeutics that combine the high and selective tumor penetration with the precision of targeted therapies in order to reach and kill cancer cells.

ICREA Memoir 2023